1. Home
  2. VLYPO vs LYEL Comparison

VLYPO vs LYEL Comparison

Compare VLYPO & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Valley National Bancorp 5.50% Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock Series B

VLYPO

Valley National Bancorp 5.50% Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock Series B

N/A

Current Price

$24.85

Market Cap

0.0

Sector

Finance

ML Signal

N/A

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

N/A

Current Price

$9.43

Market Cap

320.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VLYPO
LYEL
Founded
N/A
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
320.1M
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
VLYPO
LYEL
Price
$24.85
$9.43
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
★ $37.88
AVG Volume (30 Days)
3.8K
★ 105.0K
Earning Date
N/A
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 46.38
N/A
EPS
★ 0.57
N/A
Revenue
N/A
★ $36,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$43.75
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$24.10
$9.45
52 Week High
$25.64
$45.00

Technical Indicators

Market Signals
Indicator
VLYPO
LYEL
Relative Strength Index (RSI) 45.91 27.89
Support Level $24.74 N/A
Resistance Level $25.03 $15.38
Average True Range (ATR) 0.13 0.52
MACD -0.01 -0.09
Stochastic Oscillator 35.49 12.67

Price Performance

Historical Comparison
VLYPO
LYEL

About VLYPO Valley National Bancorp 5.50% Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock Series B

Valley National Bancorp is a bank holding company that offers a full suite of national and regional banking solutions through various commercial, private banking, retail, insurance, and wealth management financial services products. It provides personalized service and customized solutions to assist its customers with their financial service needs. The group also offers niche financial services, including loan and deposit products for homeowners associations, cannabis-related business banking, and venture banking, which offers nationally. It manages its business operations under operating segments consisting of Consumer Banking; Commercial Banking; and Treasury and Corporate Other. The group generates the majority of its revenue from the Commercial Banking Segment.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: